| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8784882 | ACERUS | Controlled release delivery system for nasal applications and method of treatment |
Feb, 2024
(4 months from now) | |
| US8877230 | ACERUS | Controlled release delivery system for nasal applications |
Feb, 2024
(4 months from now) | |
| US8574622 | ACERUS | Controlled release delivery system for nasal applications |
Feb, 2024
(4 months from now) | |
| US8784869 | ACERUS | Controlled release delivery system for nasal applications and methods of treatment |
Feb, 2024
(4 months from now) | |
| US11090312 | ACERUS | Methods of treating hypogonadism with transnasal testerosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
Mar, 2034
(10 years from now) | |
Natesto is owned by Acerus.
Natesto contains Testosterone.
Natesto has a total of 5 drug patents out of which 0 drug patents have expired.
Natesto was authorised for market use on 28 May, 2014.
Natesto is available in gel, metered;nasal dosage forms.
Natesto can be used as a method of testosterone replacement therapy comprising the step of nasally administering to a patient in need of such treatment an effective amount of testosterone gel formulation., nasal administration of a testosterone gel to a patient to treat the patient for a condition associated with a deficiency or absence of endogenous testosterone.
The generics of Natesto are possible to be released after 17 March, 2034.
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 28 May, 2014
Treatment: A method of testosterone replacement therapy comprising the step of nasally administering to a patient in need of such treatment an effective amount of testosterone gel formulation.; Nasal administrat...
Dosage: GEL, METERED;NASAL
NATESTO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic